Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IL-6 and TGF-Beta Levels in HCV Antiviral Response
NCT03882307Phase 1Unknown
- Sponsor
- Assiut University
- Start
- Oct 2022
- Primary completion
- Nov 2022
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of sofosbuvir, daclatasvir and simeprevir in hepatitis C (HCV) (2 arms), sponsored by Assiut University. Primary endpoint: Mean difference in level of interleukin-6 and transforming growth factor beta. Status: unknown.
02
Drugs
sofosbuvirdaclatasvirsimeprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT03882307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03882307.